- Home
- RIVN vs GMAB Comparison
RIVN vs GMAB Comparison
Compare RIVN & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIVN
- GMAB
- Stock Information
- Founded
- RIVN 2009
- GMAB 1999
- Country
- RIVN United States
- GMAB Denmark
- Employees
- RIVN N/A
- GMAB N/A
- Industry
- RIVN Auto Manufacturing
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- RIVN Consumer Discretionary
- GMAB Health Care
- Exchange
- RIVN Nasdaq
- GMAB Nasdaq
- Market Cap
- RIVN 16.6B
- GMAB 15.4B
- IPO Year
- RIVN 2021
- GMAB N/A
- Fundamental
- Price
- RIVN $13.46
- GMAB $27.82
- Analyst Decision
- RIVN Hold
- GMAB Buy
- Analyst Count
- RIVN 20
- GMAB 6
- Target Price
- RIVN $14.00
- GMAB $37.60
- AVG Volume (30 Days)
- RIVN 51.0M
- GMAB 1.4M
- Earning Date
- RIVN 11-06-2025
- GMAB 11-05-2025
- Dividend Yield
- RIVN N/A
- GMAB N/A
- EPS Growth
- RIVN N/A
- GMAB 77.72
- EPS
- RIVN N/A
- GMAB 21.62
- Revenue
- RIVN $5,151,000,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- RIVN $8.59
- GMAB $22.68
- Revenue Next Year
- RIVN $30.94
- GMAB $15.85
- P/E Ratio
- RIVN N/A
- GMAB $1.29
- Revenue Growth
- RIVN 2.73
- GMAB 32.97
- 52 Week Low
- RIVN $9.50
- GMAB $17.24
- 52 Week High
- RIVN $17.15
- GMAB $28.75
- Technical
- Relative Strength Index (RSI)
- RIVN 51.36
- GMAB 70.96
- Support Level
- RIVN $13.69
- GMAB $27.58
- Resistance Level
- RIVN $14.63
- GMAB $28.75
- Average True Range (ATR)
- RIVN 0.73
- GMAB 0.39
- MACD
- RIVN 0.03
- GMAB 0.19
- Stochastic Oscillator
- RIVN 36.18
- GMAB 79.28
About RIVN Rivian Automotive Inc.
Rivian Automotive Inc is an automotive manufacturer that develops and builds electric vehicles ("EVs") as well as software and services. It launches its consumer vehicle business with the R1 platform consisting of two vehicles: the R1T, and the R1S. The company has two reportable segments: Automotive, which derives the majority of revenue, and Software and Services segment. The Automotive reportable segment derives its revenues and cost of revenues from the production and sale of new EVs and the sale of regulatory credits generated by the production and sale of EVs. The Software and services reportable segment derives its revenues and cost of revenues from remarketing, vehicle repair and maintenance services, and vehicle electrical architecture and software development services.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.